Management Team

Dr. Martin Gleave, MD, FRCSC, FACS

Chief Executive Officer, PC-TRIADD
Distinguished Professor, Department of Urologic Sciences, UBC
Executive Director, Vancouver Prostate Centre
BC Leadership Chair in Prostate Cancer Research

Dr. Gleave is a clinician-scientist and urologic surgeon. His major research focus involves the study of cellular and molecular mechanisms mediating progression of prostate cancer to its lethal stage of androgen independence, and use of this information to develop integrated multimodality therapies that specifically target these mechanisms. Dr. Gleave established a role for clusterin as a cancer-related cell survival protein involved in treatment resistance and developed an inhibitor, designated OGX-011, which improved efficacy of hormone- and chemo-therapies in prostate and other cancer models. He is the scientific founder of OncoGenex Pharmaceuticals Inc.

Dr. Larry Goldenberg, CM, OBC, MD, FRCSC, FACS, FCAHS

Professor & Head, Department of Urologic Sciences, UBC
Director, Clinical Research, Vancouver Prostate Centre

Dr. Goldenberg is a urologic surgeon and clinical scientist with an international reputation for excellence in prostate cancer research and treatment. His current research involves the evaluation of the role of multiparametric MRI in prostate cancer, the potential use of focal therapy, patient education, daVinci robotic prostatectomy and novel treatments for benign prostatic hyperplasia. He has been recognized for his contributions to health care by being inducted into the Order of British Columbia and the Order of Canada.

Dr. Paul Rennie, PhD, FCAHS

Professor, Dept. of Urologic Sciences, UBC
Director, Laboratory Research, Vancouver Prostate Centre

Dr. Rennie is a PhD research scientist. His current research is aimed at determining how androgens regulate gene transcription and how to use this knowledge to prevent progression to androgen independence in prostate cancers. He is also studying prostate-specific elements of gene promoters and working to develop lenti and herpes virus-based vectors as a targeting vehicle for delivery and prostate-specific expression of genes that can control or kill prostate tumour cells.

Dr. Graeme Boniface, B. Pharm, PhD

Chief Operating Officer, Vancouver Prostate Centre
Chief Operating Officer, PC-TRIADD

Dr. Boniface s recently joined the Prostate Centre as COO, after more than 20 years in drug development in both the academic and private industry sectors. Most recently he was Senior Director of Clinical Research at QLT Inc. where he oversaw the clinical development of the company’s drug platform in Oncology, Urology, Dermatology, and Endocrinology indications. Trials conducted by his team have lead to successful regulatory marketing approvals by the US FDA, Canadian, and European agencies.

Ms. Mae Locke, Chief Financial Officer, Vancouver Prostate Centre

Mae Locke, CA, has 25 years experience in the financial field. For the last 14 years Mae has worked in the health, research and education sector for VGH, Vancouver Coastal Health Research Institute, University of British Columbia, and, for the last 10 years, the Prostate Centre. Mae received her CA in 1986 after articling with Price Waterhouse, followed by 13 years public accounting experience in diverse industries working on accounting and auditing of small private to large public companies. Emphasis included strong internal controls, accounting procedures and compliance with government and regulatory reporting.